Becker's Healthcare April 25, 2024
Mariah Taylor

The FDA approved the first new antibiotic for urinary tract infections in two decades.

The agency approved pivmecillinam tablets for adult women with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus, an April 24 FDA news release said.

The approval for Pivya was given to Utility Therapeutics, a U.S. company that acquired the rights to the drug. It is expected to become available in 2025.

In clinical trials, Pivya outperformed placebo (62% vs. 10%) and ibuprofen (66% vs. 22%) for achieving composite response and was comparable to another oral antibacterial...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article